Salarius Pharmaceuticals, Inc. (SLRX) - Dilution Analysis

10-K filing | 0.5M shares outstanding

10-Q filing | 5.9M shares outstanding

8-K filing: Salarius Pharmaceuticals, Inc. completed a public offering of common stock, pre-funded warrants, Series A warrants, and Series B warrants, closing on November 12, 2025, with net proceeds of approximately $6.3 million. ($6.3M proceeds)

S-1/A filing: Salarius is offering shares of common stock, pre-funded warrants, Series A Warrants, and Series B Warrants in a combination offering.

8-K filing: Salarius Pharmaceuticals, Inc. issued and sold an aggregate of 434,882 shares of its common stock for $2.4 million and 367,887 shares of its Common Stock for $3.8 million, since June 30, 2025. ($6.2M proceeds)

S-1/A filing: Salarius is offering shares of its common stock, Series A Warrants, Series B Warrants, and pre-funded warrants to purchase shares of common stock in a combination offering.

8-K filing: Stock split 1-for-15 | Outstanding: 7,645,594 → 509,706

10-Q filing | 7.6M shares outstanding

S-1/A filing: Salarius is filing an S-1/A to offer 10,794,765 shares of common stock, pre-funded warrants to purchase up to 10,794,765 shares of common stock, Series A Warrants to purchase up to 32,384,295 shares of common stock, Series B Warrants to purchase up to 10,794,765 shares of common stock, and Representative Warrants to purchase up to 539,738 shares of common stock.

8-K filing: Salarius issued and sold 5.5 million shares of its common stock for gross proceeds of approximately $3.8 million to C/M Capital Master Fund, LP between July 10, 2025 and July 30, 2025. ($3.8M proceeds)

S-1/A filing: Salarius is offering common stock, pre-funded warrants, and representative warrants in connection with a merger with Decoy Therapeutics Inc.

S-1/A filing: This S-1/A filing from Salarius Pharmaceuticals relates to an offering of common stock, pre-funded warrants, and representative warrants, with the proceeds intended to satisfy a financing condition for a planned merger with Decoy Therapeutics Inc.

10-Q filing | 2.1M shares outstanding

S-1/A filing: This S-1/A filing relates to an offering of Salarius' common stock and pre-funded warrants, with the intention to use the proceeds for clinical development, debt repayment, and general corporate purposes, contingent upon a merger with Decoy Therapeutics Inc. and a minimum financing of $6.0 million.

10-K filing | 1.7M shares outstanding

8-K filing: Salarius Pharmaceuticals issued and sold 141,000 shares of common stock to C/M Capital Master Fund, LP at $3.50 per share, and also issued 1,410 commitment shares. ($0.49M proceeds)

8-K filing: Salarius Pharmaceuticals entered into a merger agreement with Decoy Therapeutics and canceled a warrant to purchase 454,546 shares of its common stock for $350,000. ($0.35M proceeds)

S-1 filing: This S-1 filing outlines an offering of up to 6,733,334 shares of common stock by a selling stockholder and details a purchase agreement for up to $10.0 million of shares.

10-Q filing | 1.4M shares outstanding

8-K filing: Salarius Pharmaceuticals, Inc. sold 564,730 shares of its common stock for gross proceeds of approximately $1.5 million pursuant to an At the Market Offering Agreement. ($1.5M proceeds)

10-Q filing | 1.4M shares outstanding

8-K filing: Stock split 1-for-8 | Outstanding: 4,776,433 → 0

10-Q filing | 4.8M shares outstanding

10-K filing | 4.3M shares outstanding

10-Q filing | 3.8M shares outstanding

10-Q filing | 3.6M shares outstanding

S-3/A filing: The filing relates to a private placement of shares and warrants to Armistice, with H.C. Wainwright & Co., LLC acting as the exclusive placement agent.

S-3 filing: Salarius Pharmaceuticals, Inc. is offering shares of common stock and warrants through a private placement to Armistice, with aggregate gross proceeds of approximately $6.0 million.

8-K filing: Salarius Pharmaceuticals, Inc. completed a private placement offering, issuing 330,000 shares of common stock, pre-funded warrants to purchase 3,306,364 shares, Series A-1 warrants to purchase 3,636,364 shares, and Series A-2 warrants to purchase 3,636,364 shares, at a purchase price of $1.65 per share and accompanying Common Stock Warrants and $1.6499 per Pre-Funded Warrant and accompanying Common Stock Warrants, resulting in gross proceeds of approximately $6.0 million. ($6.0M proceeds)

10-Q filing | 2.4M shares outstanding

10-K filing | 2.5M shares outstanding

10-Q filing | 2.2M shares outstanding

8-K filing: Stock split 1-for-25 | Outstanding: 56,116,243 → 2

10-Q filing | 53.5M shares outstanding

S-3 filing: Salarius Pharmaceuticals files an S-3 registration statement for a shelf offering of common stock, preferred stock, warrants, debt securities and/or units, with a total offering price not to exceed $50,000,000.

S-3 filing: S-3 filing for 7,004,578 shares of common stock offered by the Selling Stockholders.

10-Q filing | 56.1M shares outstanding

8-K filing: Salarius Pharmaceuticals, Inc. sold 9,339,436 shares of common stock at $0.25 per share and unregistered warrants exercisable for 7,004,578 shares at $0.3399 per share in a registered direct offering and private placement, respectively, for gross proceeds of approximately $2.3 million. ($2.33M proceeds)

10-K filing | 46.7M shares outstanding

8-K filing: Salarius Pharmaceuticals, Inc. entered into an Acquisition and Strategic Collaboration Agreement with DeuteRx, LLC to purchase certain assets in exchange for cash and 1,000,000 shares of the Company's common stock.

10-Q filing | 44.8M shares outstanding

10-Q filing | 44.8M shares outstanding

8-K filing: Salarius Pharmaceuticals completed sales of 2,820,493 shares of common stock for net proceeds of $6.3 million under a prior prospectus supplement and has ceased the use of and the offering of Common Stock under, the prior prospectus supplement.

8-K filing: Salarius Pharmaceuticals distributed warrants exercisable into 142,711 shares of common stock at $15.17 per share.

10-Q filing | 44.8M shares outstanding

10-K filing | 44.7M shares outstanding

8-K filing: Salarius Pharmaceuticals, Inc. completed a public offering of 16,806,722 shares of common stock at $1.3685 per share, resulting in approximately $20.9 million of net proceeds. ($23.0M proceeds)

S-3 filing: The filing relates to an offering of 3,964,065 shares of common stock issuable upon exercise of warrants by selling stockholders.

10-Q filing | 19.8M shares outstanding

10-Q filing | 19.8M shares outstanding

10-K filing | 13.7M shares outstanding

S-1/A filing: The company is offering Class A Units (789,473), each consisting of one share of common stock and a warrant, and Class B Units (1,842,105), each consisting of one share of Series A Preferred Stock, convertible into one share of common stock and a warrant, at an assumed public offering price of $3.04 per unit; the underwriter has an option to purchase additional shares and/or warrants.

S-1/A filing: This is an S-1/A filing for an offering of Class A Units (one share of common stock and a warrant) and Class B Units (one share of Series A Preferred Stock and a warrant).

S-1 filing: The company is offering Class A Units, each consisting of one share of common stock and a warrant, and Class B Units, each consisting of one share of Series A Preferred Stock and a warrant, with an over-allotment option for additional shares of common stock and/or warrants.